ABOVE: © ISTOCK.COM, PEOPLEIMAGES
A trial of 137 patients with amyotrophic lateral sclerosis showed that a new combination of an existing drug and a supplement lessened declines in a standard measure of function over six months, according to a study published today (September 3) in The New England Journal of Medicine.
While the effect was modest and the trial early stage, “I am convinced that we are at the beginning of a new era in ALS treatment discovery,” Sabrina Paganoni, a researcher at the Sean Healey & AMG Center for ALS at Massachusetts General Hospital and Harvard Medical School who led the study, tells NPR. “[Patients] want to be able to continue to use their hands so they can cut their own food and type emails, or they want to be able to walk and climb stairs, and this is exactly what we measured in the trial.”
There are currently ...
